Total Excipient Control: A Pathway to Increased Patient Safety - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Total Excipient Control: A Pathway to Increased Patient Safety
The author focuses on how industry can build a system for Total Excipient Control.


Pharmaceutical Technology
Volume 35, pp. s34-s38

Elemental impurities. The ICH Q3D guideline and the USP general chapters on elemental impurities currently under development will head toward implementation in the next few years. These guidelines and chapters will have a significant impact on the pharmaceutical and excipient industry going forward. Many excipients contain small amounts of elemental impurities and these amounts may cause some drug products to exceed the limits proposed. As a result, some drug products may need to be reformulated. It is the opinion of IPEC that the official implementation timeline of these guidelines and chapters be delayed until appropriate characterization studies can be carried out by excipient manufacturers to fully understand what levels of these elemental impurities may exist in their excipients.

In the past, excipient users had to perform a heavy-metals limit test. This test did not provide much useful information about the actual impurity levels were in the excipients. IPEC plans to work with the industry to encourage appropriate analytical studies once the ICH Q3D limits are known so that this information can be shared with pharmaceutical users. Pharma-excipient users can then establish the appropriate calculations to determine what levels of elemental impurities may exist in the finished dosage form and whether their drug products comply with the established limits.

Other areas of focus. IPEC has identified and is working on several other excipient-control areas that need further guidance. These include:

  • QbD: excipient variability in chemical and physical properties and the effect of this variability on drug product manufacturability and performance
  • Coprocessed excipients: supporting analytical data to build safety bridging arguments to component safety data
  • Atypical actives: excipients being used as APIs that are not manufactured using ICH Q7 (4).

Conclusion

There are still many gaps in IPEC-Americas' TEC system. However, the organization is dedicated to continue to develop appropriate guidelines and whitepapers to fill these gaps and find ways of combining all of IPEC's tools into a workable system of controls that begin with excipient design and ends with patient consumption. If IPEC can do this, patient safety will surely be improved.

David R. Schoneker is vice-chair for Scientific and Regulatory Policy at the International Pharmaceutical Excipients Council of the Americas (IPEC–Americas). He is a member of Pharmaceutical Technology's editorial advisory board.

References

1. M. Steinberg et al., Regul. Toxicol. and Pharmacol. 24, 149–154 (1006).

2. FDA, Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients (Rockville, MD, May 2005).

3. C. DeMerlis et al., Pharm. Technol. 33 (11) 72–82 (2009).

4. ICH, Q7 Good Manufacturing Guide for Active Pharmaceutical Ingredients (Geneva. November 2000) Nov. 10, 2000.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here